Skip to main content
Premium Trial:

Request an Annual Quote

NY Stem Cell Foundation Partners with NIH on Undiagnosed Diseases

NEW YORK (GenomeWeb News) – The New York Stem Cell Foundation Research Institute is collaborating with the National Institutes of Health’s Undiagnosed Disease Program to create stem cell lines from patient’s cells that can be used to model and study their diseases in vitro.

NYSCF said yesterday that it plans to use its NYSCF Global Stem Cell Array to generate stem cell lines from 100 patients in the UDP and to work with UDP investigators to understand these rare diseases, and potentially find ways to treat them.

The UDP is a trans-NIH initiative, managed by the National Human Genome Research Institute, the NIH Office of Rare Diseases Research, and the NIH Clinical Center, that brings together multidisciplinary teams of scientists and clinicians to try to discover the cause of diseases in select patients with disorders that are difficult to diagnose.

NYSCF is using the array to develop a collection of induced pluripotent stem cell lines from UDP patients that will replicate human disease models. These scalable iPS cells will be standardized and will carry a patient’s genetic information, enabling researchers to compare them to their patient’s adult cells, NYSCF said.

"This collaborative effort has the potential to create new disease models that will reveal whether candidate gene variants are responsible for a patient's disease," William Gahl, director of the NIH UDP, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more